| |
|
|
|
|
|
|
|||
|
Blood, 15 September 2008, Vol. 112, No. 6, pp. 2529-2538. Prepublished online as a Blood First Edition Paper on June 25, 2008; DOI 10.1182/blood-2008-01-132506.
Submitted January 14, 2008
Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI, United States * Corresponding author; email: kpritch{at}mcw.edu.
Asthma is a co-morbid condition associated with increased rates of pain, acute chest syndrome and premature death in human sickle cell disease (SCD). We developed an experimental asthma model in SCD and control mice expressing either normal human or murine hemoglobin to determine its effect on mortality and lung pathology. To induce lung inflammation, experimental mice were sensitized to ovalbumin (OVA) by subcutaneous OVA implantation (Sen), allowed 2 wks to recover and then divided into 2 groups, each receiving over a subsequent 10 day period, the same dosage of aerosolized OVA but 2 different levels of exposure; 15 min (LoSen) and 30 min (HiSen). During recovery, 10% of SCD mice died compared to no deaths in control mice. An additional 30% of HiSen SCD mice died during aerosolization compared to 10% in LoSen SCD. Histological indices of lung inflammation (e.g., eosinophil recruitment, airway and vessel wall thickening, immunoreactive TGF
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2008 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||